tbuckley/cabot-search huggingface dataset:
Newly-Diagnosed Versus Non-Initial Episodes of Thrombotic Thrombocytopenic Purpura: A Comparison of Presenting Clinical Characteristics and Response to Treatment.
Authors: Alberto Alvarez-Larrán, Julio del Río-Garma, Josep Muncunill, Javier de la Rubia, Manuel Hernández-Jodrá, Misericordia Pujol, José González-Porras, José Mateo, Pilar Rodríguez-Vicente, Aurora Viejo, Francisco Peña, Enric Contreras, Arturo Pereira
Journal: Blood (2008)
临床证据（15）术后肺部感染
Authors: AndrewSmith, 许力, 黄宇光
Journal: BMJ (2003)

背景知识 定义 诊断术后肺部感染须具备以下3个或3个以上症状:咳嗽、咳痰、气促、胸痛、体温高于38℃以及脉搏快于每分钟100次。肺炎的诊断需结合胸部X线征象。 发病率/流行情况 术后肺部并发症的发病率与报道者调查的深入程度有关。一项研究发现,在接受开腹胆囊切除
Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes
Authors: Michael Leukam, James Godfrey, Sravya Tumuluru, Girish Venkataraman, Sonali M. Smith, Riyue Bao, Justin Kline
Journal: Blood (2019)
T Cell Landscape of Immune Aplastic Anemia Reveals a Convergent Antigen-Specific Signature
Authors: Jani Huuhtanen, Sofie Lundgren, Mikko A Keränen, Xingmin Feng, Cassandra M Kerr, Emmi Jokinen, Markus Heinonen, Paula Savola, Tiina Kelkka, Freja Ebeling, Georgina L Ryland, Lucy Fox, Piers Blombery, Eva Hellstrom Lindberg, Neal S. Young, Jaroslaw P. Maciejewski, Harri Lähdesmäki, Satu Mustjoki
Journal: Blood (2019)
Multi-institutional study of reirradiation with proton beam radiotherapy for non-small cell lung cancer.
Authors: Abigail T. Berman, Christine Agnes Martin, Haibo Lin, Stefan Both, Corey J. Langer, Kristi Varillo, Ramesh Rengan, Stephen M. Hahn, Marcio Fagundes, William F. Hartsell, Charles B. Simone, John Peter Plastaras
Journal: Journal of Clinical Oncology (2013)

7578 Background: The management of recurrent non-small cell lung cancer (NSCLC) in the setting of prior radiation (RT) is complex. Proton radiotherapy (PRT) is ideally suited to minimize toxicity by sparing dose to previously-irradiated organs. Herein we report the safety and feasibility of PRT for NSCLC reirradiation. Methods: Patients (pts) with recurrent NSCLC in or near their prior RT field were identified in three proton centers. An interval of 3 months was required between original RT course and PRT start. Pts were classified as low volume (LV, clinical target volume [CTV] ≤250 cc) or high volume (HV, CTV &gt;250 cc). PRT was deemed infeasible if pts were unable to tolerate 15% of fractions or complete all treatments in &lt;10 days of estimated end date and without a break ≥5 days. Results: Between 10/2010-11/2012, 24 pts were reirradiated, with 12 on a prospective trial of PRT for reirradiation. Median age was 69 (51-89). Histologies included squamous cell carcinoma (50%), adenocarcinoma (39%), and other (13%). Stage at initial diagnosis was I (8.3%), II (20.8%), III (50%), IV (12.5%), and unknown (8.3%). All pts were ECOG PS 0-2. Median prior dose was 62.4 Gy (30.6-80); 1 pt had 2 prior RT courses. The majority of pts (63%) were LV (median CTV 75.3, 11.9-236) and 38% were HV (359, 297.8-695.7). Concurrent systemic therapy (platinum-based or erlotinib) was given in 63%. Median PRT dose was 66.6 Gy (36-74). Average mean lung dose was 7.6 and 10.8 Gy and lung volume receiving 5 and 20 Gy was 16 and 24% and 26 and 33% in LV and HV pts, respectively. Follow up was &gt;60 days in 17 pts. Overall, 46% of pts were hospitalized. PRT was infeasible in 3/9 HV and 1/15 LV pts. In HV pts, there were 2 grade 5 toxicities (hemoptysis and neutropenic fever). There was 1 in-field and 4 other thoracic recurrences, and 5 and 4 deaths in LV and HV pts, respectively. Conclusions: Preliminary results show promising early outcomes and acceptable toxicity in LV pts; due to the toxicity seen in HV pts, additional exclusion criteria were added for NSCLC pts in the ongoing trial. NSCLC reirradiation should continue to be studied in prospective trials to identify pts that may derive clinical benefit. Mature follow up is needed prior to standardizing NSCLC reirradiation with PRT.
GliomaDB: A Web Server for Integrating Glioma Omics Data and Interactive Analysis
Authors: Yadong Yang, Yang Sui, Bingbing Xie, Hongzhu Qu, Xiangdong Fang
Journal: Genomics Proteomics & Bioinformatics (2019)

Gliomas are one of the most common types of brain cancers. Numerous efforts have been devoted to studying the mechanisms of glioma genesis and identifying biomarkers for diagnosis and treatment. To help further investigations, we present a comprehensive database named GliomaDB. GliomaDB includes 21,086 samples from 4303 patients and integrates genomic, transcriptomic, epigenomic, clinical, and gene-drug association data regarding glioblastoma multiforme (GBM) and low-grade glioma (LGG) from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), the Chinese Glioma Genome Atlas (CGGA), the Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), the US Food and Drug Administration (FDA), and PharmGKB. GliomaDB offers a user-friendly interface for two main types of functionalities. The first comprises queries of (i) somatic mutations, (ii) gene expression, (iii) microRNA (miRNA) expression, and (iv) DNA methylation. In addition, queries can be executed at the gene, region, and base level. Second, GliomaDB allows users to perform survival analysis, coexpression network visualization, multi-omics data visualization, and targeted drug recommendations based on personalized variations. GliomaDB bridges the gap between glioma genomics big data and the delivery of integrated information for end users, thus enabling both researchers and clinicians to effectively use publicly available data and empowering the progression of precision medicine in glioma. GliomaDB is freely accessible at http://bigd.big.ac.cn/gliomaDB.
Involvement of NK cell molecular signatures in favorable prognosis of breast cancer patients.
Authors: Maria Libera Ascierto, Michael O Idowu, Yingdong Zhao, Davide Bedognetti, Paolo Antonio Ascierto, Harry Douglas Bear, Ena Wang, Franco Marincola, Andrea De Maria, Masoud Manjili
Journal: Journal of Clinical Oncology (2012)

10565 Background: Tumor cell recognition by NK cells is mediated by the interaction of activating and inhibitory NK cell receptors with their ligands expressed on tumor cells. In addition, NK cells express adhesion molecules that facilitate formation of the immunological synapse with the tumor targets. Here, we investigated whether the coordinate expression of NK activating receptors and adhesion molecules could provide a signature to segregate breast cancer patients into relapse and relapse-free outcomes. Methods: Gene expression profiling, RT-PCR screening and survival analysis were performed on RNA extracted from primary breast cancers. Tumors were obtained from patients experiencing either 5-8 years relapse-free survival or tumor relapse within 1-3 years following initial treatment. Results: Tumors from patients with a favorable prognosis were characterized by increased expression of genes involved in NK cell interaction with tumor cells and its activation signaling. In particular, up-regulation of Natural Cytotoxicity Receptors (NCRs), leukocyte function-associated antigen 1 (LFA-1), CD226 (DNAM-1) and CD96 was observed in relapse-free patients. Thus, the expression of the NK activating receptors and relevant adhesion molecules involved in NK cell:target interactions can predict relapse free survival in breast cancer patients. Conclusions: Results from the present study, highlighted the effector cooperation between the innate and adaptive immune components within the tumor microenvironment. The NK cells parameters identified in this study, together with the prognostic B and T cell signatures previously reported by us, represent a powerful tool for predicting breast cancer outcome which might be easily introduced in clinical practice.
Retroviral-Mediated Gene Transfer of CD18 into Hematopoietic Stem Cells in Dogs with Canine Leukocyte Adhesion Deficiency Reverses the Severe Deficiency Phenotype.
Authors: Mehreen Hai, Thomas R. Bauer, Yu-chen Gu, Laura M. Tuschong, Robert A. Sokolic, Dennis D. Hickstein
Journal: Blood (2004)
Sir William Osler (1849–1919) — The Uses of History and the Singular Beneficence of Medicine
Authors: Charles S. Bryan, Scott H. Podolsky
Journal: New England Journal of Medicine (2019)

A century after his death, Sir William Osler is revered for his efforts to place clinical medicine on a rational foundation, his transformation of graduate medical education, and his attempt to keep medicine informed by humanism, even as it became ever more scientific.
Increased ABCG2 Expression Could Be Responsible for Resistance to Imatinib Mesylate in Patients with Chronic Myeloid Leukemia Who Do Not Have Mutations in BCR-ABL Kinase Domain
Authors: Poonkuzhali Balasubramanian, Preetha Markose, Ezhilarasi Chendamarai, Vikram Mathews, Vivi Srivastava, Shaji R Velayudhan, Kavitha M Lakshmi, Auro Viswabandhya, Biju George, Alok Srivastava, Mammen Chandy
Journal: Blood (2008)
Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis
Authors: Elena Mylonas, Kenichi Yoshida, Mareike Frick, Kaja Hoyer, Friederike Christen, Jaspal Kaeda, Matthias Obenaus, Daniel Nörenberg, Cornelius Hennch, Willy Chan, Yotaro Ochi, Yuichi Shiraishi, Yusuke Shiozawa, Thorsten Zenz, Christopher C. Oakes, Birgit Sawitzki, Michaela Schwarz, Lars Bullinger, Philipp Le Coutre, Matthew John Jerome Rose-Zerilli, Seishi Ogawa, Frederik Damm
Journal: Blood (2019)
An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring
Authors: R. Starkman, S. Alibhai, R. A. Wells, M. Geddes, N. Zhu, M. M. Keating, B. Leber, L. Chodirker, M. Sabloff, G. Christou, H. A. Leitch, E. St-Hilaire, N. Finn, A. Shamy, K. Yee, J. Storring, T. Nevill, R. Delage, M. Elemary, V. Banerji, M. Lenis, A. Kirubananthaan, A. Mamedov, L. Zhang, K. Rockwood, R. Buckstein
Journal: Leukemia (2019)
Characterization of T Cell Epitopes of the Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) in Acute Myeloid Leukemia.
Authors: Michael Schmitt, Li Li, Mark Ringhoffer, Thomas Barth, Markus Wiesneth, Hartmut Dohner, Jochen Greiner
Journal: Blood (2004)
Echocardiographic study of the Duchenne type of progressive muscular dystrophy.
Authors: Kyozo Ishikawa, Hiroshi Kanemitsu, Tadayuki Ishihara, Takeshi Tamura, Hideyo Shimada, Mitsuru Inoue
Journal: Circulation (1981)

The present study was undertaken in an attempt to clarify whether or not any relationship exists between the echocardiographic indices of cardiac function and the severity of progressive muscular dystrophy of the Duchenne type (PMD). A total of 75 patients with PMD was used for analysis. Among the echocardiographic parameters measured in the study, the maximal diastolic endocardial velocity (DEVM) and ejection fraction (EF) revealed a gradual decreasing tendency with increasing severity of the disorder. It can be concluded therefore that DEVM and EF may represent useful indices in the assessment of cardiac function in PMD.
Abstract 10607: Effects of Low-Dose Methotrexate on Brachial Artery Echogenicity and Grayscale Texture in HIV-Infected Individuals at Increased Cardiovascular Disease Risk: AIDS Clinical Trials Group Study A5314
Authors: James H Stein, Eunice Yeh, Joanne M Weber, Claudia E Korcarz, Paul M Ridker, Ahmed Tawakol, Priscilla Y Hsue, Judith S Currier, Heather Ribaudo, Carol K Mitchell
Journal: Circulation (2018)

Background: Excess atherosclerotic cardiovascular disease (ASCVD) risk in people with human immunodeficiency virus (HIV) infection may be related to inflammation and disordered immune regulation. W...
In AML, Cbl Serves as Nexus for Signaling from Flt3, and Is Required for Coupling JNK1 in a Pathway of Survival and Proliferation Involving c-jun/AP-1.
Authors: Amy D. Hartman, Annique Wilson-Weekes, Attaya Suvannasankha, Gem S. Burgess, Kathryn J. Hincher, Larry D. Cripe, H. Scott Boswell
Journal: Blood (2005)
Image Gallery: Otic lichen planus complicated by tympanic membrane rupture successfully treated with topical 1% tacrolimus
Authors: B. Tran, D. Guffey, M. Noland
Journal: British Journal of Dermatology (2019)

Funding sources: none. Conflicts of interest: none declared. Dear Editor, A 75‐year‐old female patient with a 20‐year history of presumed cutaneous and mucosal lichen planus (LP) and a 4‐year history of bilateral conductive hearing loss presented with acute bilateral otalgia, otorrhoea and (a) violaceous flat‐topped papules on the lower extremities. (b) Otoscopy revealed perforated bilateral tympanic membranes (TMs). The patient had no history of barotrauma or systemic disease that predisposed her to TM rupture. She was diagnosed with otic LP. This is the first reported case of otic LP complicated by TM perforation.1 At the 2‐month follow‐up, her aural symptoms improved and TM perforations completely resolved with compounded topical 1% tacrolimus in mineral oil. ...
Percutaneous cholangiography
Authors: V M Sitenko, A I Nechaĭ, V M Trofimov
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Supporting the school climate strike with a public health “work-in”
Authors: Gerry McCartney, Rebecca Campbell, Ann Conacher, Phil Mackie
Journal: BMJ (2019)

Since August 2018, schoolchildren around the world have been participating in a “school strike for climate” to call for action in accordance with the United Nations Paris agreement.1 Participating in a strike, like other forms of direct action and protest, can be a very powerful means for groups who are otherwise disempowered to gain power and influence …
Efficacy and Determinants of Response to HER Kinase Inhibition in<i>HER2</i>-Mutant Metastatic Breast Cancer
Authors: Lillian M. Smyth, Sarina A. Piha-Paul, Helen H. Won, Alison M. Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I. Shapiro, Dejan Juric, Ingrid A. Mayer, Carlos L. Arteaga, Macarena I. de la Fuente, Adam M. Brufksy, Iben Spanggaard, Morten Mau-Sørensen, Monica Arnedos, Victor Moreno, Valentina Boni, Joohyuk Sohn, Lee S. Schwartzberg, Xavier Gonzàlez-Farré, Andrés Cervantes, François-Clement Bidard, Alexander N. Gorelick, Richard B. Lanman, Rebecca J. Nagy, Gary A. Ulaner, Sarat Chandarlapaty, Komal Jhaveri, Elena I. Gavrila, Catherine Zimel, S. Duygu Selcuklu, Myra Melcer, Aliaksandra Samoila, Yanyan Cai, Maurizio Scaltriti, Grace Mann, Feng Xu, Lisa D. Eli, Melanie Dujka, Alshad S. Lalani, Richard Bryce, José Baselga, Barry S. Taylor, David B. Solit, Funda Meric-Bernstam, David M. Hyman
Journal: Cancer Discovery (2019)

Abstract HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of multiple HER2-activating events, as well as gatekeeper alterations, were observed at disease progression in a high proportion of patients deriving clinical benefit from neratinib. Collectively, these data define HER2 mutations as a therapeutic target in breast cancer and suggest that coexistence of additional HER signaling alterations may promote both de novo and acquired resistance to neratinib. Significance: HER2 mutations define a targetable breast cancer subset, although sensitivity to irreversible HER kinase inhibition appears to be modified by the presence of concurrent activating genomic events in the pathway. These findings have implications for potential future combinatorial approaches and broader therapeutic development for this genomically defined subset of breast cancer. This article is highlighted in the In This Issue feature, p. 161
Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE<sup>-/-</sup> mice
Authors: Chuanrui Ma, Ronglin Xia, Shu Yang, Lipei Liu, Jing Zhang, Ke Feng, Yuna Shang, Jingtian Qu, Lingwei Li, Ning Chen, Shixin Xu, Wenwen Zhang, Jingyuan Mao, Jihong Han, Yuanli Chen, Xiaoxiao Yang, Yajun Duan, Guanwei Fan
Journal: Theranostics (2019)

Background and Purpose: Atherosclerosis is an underlying cause of coronary heart disease. Foam cell, a hallmark of atherosclerosis, is prominently derived from monocyte-differentiated macrophage, and vascular smooth muscle cells (VSMCs) through unlimitedly phagocytizing oxidized low-density lipoprotein (oxLDL). Therefore, the inhibition of monocyte adhesion to endothelium and uptake of oxLDL might be a breakthrough point for retarding atherosclerosis. Formononetin, an isoflavone extracted from Astragalus membranaceus, has exhibited multiple inhibitory effects on proatherogenic factors, such as obesity, dyslipidemia, and inflammation in different animal models. However, its effect on atherosclerosis remains unknown. In this study, we determined if formononetin can inhibit atherosclerosis and elucidated the underlying molecular mechanisms. Methods: ApoE deficient mice were treated with formononetin contained in high-fat diet for 16 weeks. After treatment, mouse aorta, macrophage and serum samples were collected to determine lesions, immune cell profile, lipid profile and expression of related molecules. Concurrently, we investigated the effect of formononetin on monocyte adhesion, foam cell formation, endothelial activation, and macrophage polarization in vitro and in vivo. Results: Formononetin reduced en face and aortic root sinus lesions size. Formononetin enhanced lesion stability by changing the composition of plaque. VSMC- and macrophage-derived foam cell formation and its accumulation in arterial wall were attenuated by formononetin, which might be attributed to decreased SRA expression and reduced monocyte adhesion. Formononetin inhibited atherogenic monocyte adhesion and inflammation. KLF4 negatively regulated the expression of SRA at transcriptional and translational level. Conclusions: Our study demonstrate that formononetin can substantially attenuate the development of atherosclerosis via regulation of interplay between KLF4 and SRA, which suggests the formononetin might be a novel therapeutic approach for inhibition of atherosclerosis.
Activated but Not Quiescent Hematopoietic Stem Cells Rely Readily on Glycolysis As Their Main Source of Energy
Authors: Tasleem Arif, Raymond Liang, Maio Lin, Svetlana Kalmikova, Artem Kasianov, Vijay Menon, Dmitri Papatsenko, Saghi Ghaffari
Journal: Blood (2019)
Acute Erythroid Leukemia (AEL): A Clinical, Morphological, Cytogenetic and Follow-Up Study of 69 Patients.
Authors: Elisa Luño, Carmen Sanzo, Francesc Sole, Mirian Gonzalez, Isabel Granada, Blanca Espinet, Cristina Chamorro, Rosa Collado, Ana Cabello, M. Jose Calasanz, Eva Arranz, Juan M. Bergua
Journal: Blood (2005)
The Role of CEBPα Mutations in the Progression of Myeloid Leukemias.
Authors: Lee-Yung Shih, Chein-Fuang Huang, Der-Cherng Liang, Tung-Liang Lin, Jin-Hou Wu, Po-Nan Wang, Po Dunn, Ming-Chung Kuo, Chung-Chih Tang
Journal: Blood (2004)
Association of Skin and Blood Dendritic Cells with Acute Graft Versus Host Disease after Human Haematopoetic Cell Transplantation.
Authors: Susanne Auffermann-Gretzinger, Lars Eger, Martin Bornhaeuser, Christian Thiede, Knuth Schaekel, Uta Oelschlaegel, Thomas Illmer, Markus Schaich, Gerhard Ehninger
Journal: Blood (2004)
Mitochondria-acting nanomicelles for destruction of cancer cells via excessive mitophagy/autophagy-driven lethal energy depletion and phototherapy
Authors: Ya-Xuan Zhu, Hao-Ran Jia, Ge Gao, Guang-Yu Pan, Yao-Wen Jiang, Penglin Li, Ningxuan Zhou, Chengcheng Li, Cong She, Nathan W. Ulrich, Zhan Chen, Fu-Gen Wu
Journal: Biomaterials (2019)
Antibody Therapy Targeting RAN Proteins Rescues C9 ALS/FTD Phenotypes in C9orf72 Mouse Model
Authors: Lien Nguyen, Fabio Montrasio, Amrutha Pattamatta, Solaleh Khoramian Tusi, Olgert Bardhi, Kevin D. Meyer, Lindsey Hayes, Katsuya Nakamura, Monica Banez-Coronel, Alyssa Coyne, Shu Guo, Lauren A. Laboissonniere, Yuanzheng Gu, Saravanakumar Narayanan, Benjamin Smith, Roger M. Nitsch, Mark W. Kankel, Mia Rushe, Jeffrey Rothstein, Tao Zu, Jan Grimm, Laura P.W. Ranum
Journal: Neuron (2019)
Prevalence of a First-Degree Relative With Colorectal Cancer and Uptake of Screening Among Persons 40 to 54 Years Old
Authors: Korbinian Weigl, Kaja Tikk, Michael Hoffmeister, Jochen Hampe, Svitlana Igel, Frank Kolligs, Stefanie J. Klug, Ulrich Mansmann, Oliver Müller, Jutta M. Nagel, Marcus Pichler, Matthias Schwab, Dirk Schweigler, Anna-Magdalena Stephan, Enrico N. De Toni, Hermann Brenner
Journal: Clinical Gastroenterology and Hepatology (2019)
Клинико-эндоскопические параллели при неспецифическом язвенном колите
Authors: Yu.M. Stepanov, I.V. Psarova
Journal: GASTROENTEROLOGY (2019)

Актуальность. В настоящее время не существует идеального способа для оценки активности неспецифического язвенного колита (НЯК), что и обусловливает актуальность изучения особенностей течения данной патологии со сравнительным анализом типичных клинических и эндоскопических проявлений. Цель работы — оптимизация диагностики НЯК. Материалы и методы. Обследованы 60 пациентов с подтвержденным диагнозом НЯК — 31 (51,7 %) мужчина и 29 (48,3 %) женщин в возрасте от 21 до 63 лет (средний показатель составил (40,28 ± 1,34) года), из них 52 (86,6 %) пациента трудоспособного возраста. Результаты. Распределение больных по оценке комбинированного индекса Mayo показало, что 36 (60,0 %) пациентов имели умеренную степень обострения НЯК, средний показатель составил (8,12 ± 0,29) балла; в 24 (40,0 %) случаях диагностирована тяжелая степень, среднее значение индекса составило (11,38 ± 0,48) балла. Корреляционный анализ индексов активности НЯК показал взаимосвязь степени активности заболевания согласно комбинированному индексу Mayo с клинической активностью по шкале D. Rachmilewitz (r = 0,459; р &lt; 0,01), тяжестью атаки НЯК по критериям S. Truelove и L. Witts (r = 0,526; р &lt; 0,01) и эндоскопической активностью по частичному индексу Mayo (r = 0,598; р &lt; 0,01). Выводы. Установленные клинико-эндоскопические взаимосвязи при НЯК подтверждают необходимость комплексного подхода к диагностике этого заболевания. С учетом того, что степень распространения воспаления и тяжесть атаки НЯК влияют на тактику ведения пациента и оценку лечебных мероприятий, клинические и эндоскопические показатели полезны для стандартизации активности заболевания.
Risk of readmission and death in patients admitted with new-onset versus worsening heart failure: insights from a nationwide cohort
Authors: J H Jawad Haider Butt, E L Fosbol, C Andersson, T A Gerds, J J V Mcmurray, M C Petrie, F Gustafsson, C Madelaire, S L Kristensen, G H Gislason, C Torp-Pedersen, L Kober, M Schou
Journal: European Journal of Heart Failure (2019)